NAMSW
NewAmsterdam Pharma Company N.V. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.03
52W High
$30.45
52W Low
$7.16
50-Day MA
$22.25
200-Day MA
$21.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V. is a pioneering clinical-stage biopharmaceutical firm focused on developing innovative therapeutics for cardiometabolic diseases, particularly dyslipidemia, which significantly contributes to cardiovascular risk. Leveraging a robust research and development framework and a rigorous scientific approach, the company is strategically positioned to seek regulatory approval for its unique drug candidates. By targeting substantial unmet medical needs within this essential therapeutic area, NewAmsterdam aims to improve patient outcomes while creating long-term value for shareholders, making it an attractive prospect for institutional investors in the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $22.57M |
| Gross Profit (TTM) | $22.57M |
| EBITDA | $-214.95M |
| Operating Margin | -1922.00% |
| Return on Equity | -29.50% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.97 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | 0 |
| Float | $80.70M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
84.41%
HV 20-Day
132.61%
HV 30-Day
118.03%
HV 60-Day
111.64%
HV Rank
96.0%
Volatility is currently contracting
Data last updated: 5/25/2026